Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]

Autor: de Azambuja, E., Piccart-Gebhart, M., Fielding, S., Townend, J., Hillman, D.W., Colleoni, M., Roylance, R., Kelly, C.M., Lombard, J., El-Abed, S., Choudhury, A., Korde, L., Vicente, M., Chumsri, S., Rodeheffer, R., Ellard, S.L., Wolff, A.C., Holtschmidt, J., Lang, I., Untch, M., Boyle, F., Xu, B., Werutsky, G., Tujakowski, J., Huang, C.-S., Baruch, N.B., Bliss, J., Ferro, A., Gralow, J., Kim, S.-B., Kroep, J.R., Krop, I., Kuemmel, S., McConnell, R., Moscetti, L., Knop, A.S., van Duijnhoven, F., Gomez, H., Cameron, D., Di Cosimo, S., Gelber, R.D., Moreno-Aspitia, A.

Publikováno v: In ESMO Open November 2024 9(11)

The singular French PCSK9-p.Ser127Arg gain-of-function variant: A significant player in cholesterol levels from a 775-year-old common ancestor.

Autor: Azar Y; Paris Cité University and Sorbonne Paris Nord University, INSERM UMRS 1148, Laboratory for Vascular Translational Science (LVTS), F-75018, Paris, France; Saint-Joseph University of Beirut, Faculty of Pharmacy, Laboratory of Biochemistry and Molecular Therapeutics (LBTM), Beirut, 1004 2020, Lebanon., Ludwig TE; CHRU and Brest University, Inserm, EFS, INSERM UMR 1078, GGB, F-29200, Brest, France., Le Bon H; Paris Cité University and Sorbonne Paris Nord University, INSERM UMRS 1148, Laboratory for Vascular Translational Science (LVTS), F-75018, Paris, France., Strøm TB; Oslo University Hospital, Department of Medical Genetics, 0450, Oslo, Norway., Bluteau O; Sorbonne University, Faculty of Medicine Pitié-Salpêtrière, INSERM UMRS 1166, F-75005, Paris, France., Di-Filippo M; Lyon-1 University, INSERM U1060, CarMeN Laboratory, Oullins, F-69600, France; Hospices Civil de Lyon, Department of Biochemistry and Molecular Biology, Bron, F-69002, France., Carrié A; Sorbonne University, Faculty of Medicine Pitié-Salpêtrière, INSERM UMRS 1166, F-75005, Paris, France., Chtioui H; Aix-Marseille University, La Conception Hospital, Nutrition Department, AP-HM, INSERM, INRAE, C2VN, Marseille, F-13001, France., Béliard S; Aix-Marseille University, La Conception Hospital, Nutrition Department, AP-HM, INSERM, INRAE, C2VN, Marseille, F-13001, France., Marmontel O; Lyon-1 University, INSERM U1060, CarMeN Laboratory, Oullins, F-69600, France; Hospices Civil de Lyon, Department of Biochemistry and Molecular Biology, Bron, F-69002, France., Fonteille A; Centre Hospitalier d'Annecy Genevois, Médecine Interne, Epagny Metz-Tessy, F-74370, France., Gebhart M; CHU Jean Minjoz, F-25000, Besançon, France., Peretti N; Lyon-1 University, INSERM U1060, CarMeN Laboratory, Oullins, F-69600, France; Hospices Civil de Lyon, Department of Pediatric Gastroenterology-Hepatology and Nutrition, Bron, F-69002, France., Moulin P; Lyon-1 University, INSERM U1060, CarMeN Laboratory, Oullins, F-69600, France; Hospices Civil de Lyon, Department of Endocrinology and Nutrition, Bron, F-69002, France., Ferrières J; Toulouse Rangueil University Hospital, Department of Cardiology, INSERM, UMR 1295, F-31400, Toulouse, France., Pradignac A; CHU of Strasbourg, Department of Internal Medicine, Endocrinology and Nutrition, Strasbourg, F-67000, France., Farnier M; University of Bourgogne Franche-Comté, PEC2 Team, Dijon, Cedex, F-25000, France., Gallo A; Sorbonne University, Faculty of Medicine Pitié-Salpêtrière, INSERM UMRS 1166, F-75005, Paris, France., Yelnik C; CHUR of Lille, Department of Internal Medicine and Immunology, Lille, France; INSERM, UMR 1167 RID-AGE, Lille, F-59000, France., Blom D; University of Cape Town, Division of Lipidology and Cape Heart Institute, Cape Town, 7925, South Africa., Génin E; CHRU and Brest University, Inserm, EFS, INSERM UMR 1078, GGB, F-29200, Brest, France., Bogsrud MP; Oslo University Hospital, Department of Medical Genetics, 0450, Oslo, Norway., Leren TP; Oslo University Hospital, Department of Medical Genetics, 0450, Oslo, Norway., Boileau C; Paris Cité University and Sorbonne Paris Nord University, INSERM UMRS 1148, Laboratory for Vascular Translational Science (LVTS), F-75018, Paris, France; Bichat-Claude Bernard Hospital, Genetic Department, AP-HP, F-75018, Paris, France., Abifadel M; Paris Cité University and Sorbonne Paris Nord University, INSERM UMRS 1148, Laboratory for Vascular Translational Science (LVTS), F-75018, Paris, France; Saint-Joseph University of Beirut, Faculty of Pharmacy, Laboratory of Biochemistry and Molecular Therapeutics (LBTM), Beirut, 1004 2020, Lebanon., Rabès JP; Paris Cité University and Sorbonne Paris Nord University, INSERM UMRS 1148, Laboratory for Vascular Translational Science (LVTS), F-75018, Paris, France; Paris-Saclay University and Versailles-Saint-Quentin-en-Yvelines University, Ambroise Paré University Hospital, Biochemistry and Molecular Genetics Department, AP-HP, F-92104, Boulogne-Billancourt, France., Varret M; Paris Cité University and Sorbonne Paris Nord University, INSERM UMRS 1148, Laboratory for Vascular Translational Science (LVTS), F-75018, Paris, France. Electronic address: mathilde.varret@inserm.fr.

Publikováno v: Atherosclerosis [Atherosclerosis] 2024 Dec; Vol. 399, pp. 118596. Date of Electronic Publication: 2024 Sep 13.

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019

Autor: Burstein, H.J. ^*, Curigliano, G. ^*, Loibl, S., Dubsky, P., Gnant, M., Poortmans, P., Colleoni, M., Denkert, C., Piccart-Gebhart, M., Regan, M., Senn, H.-J., Winer, E.P., Thurlimann, B.

Publikováno v: In Annals of Oncology October 2019 30(10):1541-1557

Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium.

Autor: Brandão M; Academic Trials Promoting Team (ATPT), Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium.; Medical Oncology Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium., Martins-Branco D; Academic Trials Promoting Team (ATPT), Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium., De Angelis C; Academic Trials Promoting Team (ATPT), Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium.; Clinical Oncology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy., Vuylsteke P; CHU UCL Namur, Site Ste Elisabeth, UC Louvain, Namur, Belgium.; Department of Internal Medicine, University of Botswana, Gaborone, Botswana., Gelber RD; Department of Data Science, Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health, Frontier Science Foundation, Boston, USA., Van Damme N; Department of Data Science, Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health, Frontier Science Foundation, Boston, USA., van Walle L; Belgian Cancer Registry, Brussels, Belgium., Ferreira AR; Breast Unit, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal.; Católica Medical School, Universidade Católica Portuguesa, Rio de Mouro, Portugal., Lambertini M; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy.; Department of Medical Oncology, U.O. Clinica Di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Poggio F; Department of Medical Oncology, U.O. Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Verhoeven D; Medical Oncology, AZ Klina, University of Antwerp, Antwerp, Belgium., Barbeaux A; Medical Oncology, CHR Verviers East Belgium, Verviers, Belgium., Duhoux FP; Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Brussels, Belgium., Wildiers H; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute and University Hospitals Leuven, Louvain, Belgium., Caballero C; Breast International Group, Brussels, Belgium., Awada A; Medical Oncology Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium., Piccart-Gebhart M; Medical Oncology Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium., Punie K; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute and University Hospitals Leuven, Louvain, Belgium., de Azambuja E; Academic Trials Promoting Team (ATPT), Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium. evandro.deazambuja@hubruxelles.be.; Medical Oncology Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium. evandro.deazambuja@hubruxelles.be.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Jul; Vol. 206 (1), pp. 207.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

Autor: Curigliano, G ^{*, †}, Burstein, H.J. ^†, Winer, E.P., Gnant, M., Dubsky, P., Loibl, S., Colleoni, M., Regan, M.M., Piccart-Gebhart, M., Senn, H.-J., Thürlimann, B., André, F., Baselga, J., Bergh, J., Bonnefoi, H., Brucker, S.Y., Cardoso, F., Carey, L., Ciruelos, E., Cuzick, J., Denkert, C., Di Leo, A., Ejlertsen, B., Francis, P., Galimberti, V., Garber, J., Gulluoglu, B., Goodwin, P., Harbeck, N., Hayes, D.F., Huang, C.-S., Huober, J., Khaled, H., Jassem, J., Jiang, Z., Karlsson, P., Morrow, M., Orecchia, R., Osborne, K.C., Pagani, O., Partridge, A.H., Pritchard, K., Ro, J., Rutgers, E.J.T., Sedlmayer, F., Semiglazov, V., Shao, Z., Smith, I., Toi, M., Tutt, A., Viale, G., Watanabe, T., Whelan, T.J., Xu, B.

Publikováno v: In Annals of Oncology August 2017 28(8):1700-1712